Bristol-Myers Squibb (BMY) Financials

$48.26 +0.41 (+0.86%)

Closing price 03:59 PM Eastern

Extended Trading

$48.27 +0.01 (+0.02%)

As of 07:56 PM Eastern

Annual Income Statements for Bristol-Myers Squibb

This table shows Bristol-Myers Squibb's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	-8,948	8,025	6,327	6,994	-9,015	3,439	4,920	1,007	4,457	1,565
Consolidated Net Income / (Loss)	-8,933	8,040	6,345	7,014	-8,995	3,460	4,947	975	4,507	1,631
Net Income / (Loss) Continuing Operations	-8,933	8,040	6,345	7,014	-8,995	3,460	4,947	975	4,507	1,631
Total Pre-Tax Income	-8,379	8,440	7,713	8,098	-6,871	4,975	5,968	5,131	5,915	2,077
Total Operating Income	-7,486	7,282	8,289	7,378	-9,185	5,913	5,114	3,446	4,467	1,890
Total Gross Profit	20,959	33,400	35,207	35,286	30,745	18,067	16,094	14,762	14,458	12,651
Total Revenue	48,300	45,006	46,159	46,385	42,518	26,145	22,561	20,776	19,427	16,560
Operating Revenue	48,300	45,006	46,159	46,385	42,518	26,145	22,561	20,776	19,427	14,045
Total Cost of Revenue	27,341	11,606	10,952	11,099	11,773	8,078	6,467	6,014	4,969	3,909
Operating Cost of Revenue	27,341	11,606	10,952	11,099	11,773	8,078	6,467	6,014	4,969	3,909
Total Operating Expenses	28,445	26,118	26,918	27,908	39,930	12,154	10,980	11,316	9,991	10,761
Selling, General & Admin Expense	8,414	7,772	7,814	7,690	7,661	4,871	4,551	4,751	4,979	4,841
Research & Development Expense	11,159	9,299	9,509	10,195	10,048	6,148	6,332	6,468	5,012	5,920
Amortization Expense	8,872	9,047	9,595	10,023	9,688	1,135	97	97	-	-
Total Other Income / (Expense), net	-893	1,158	-576	720	2,314	-938	854	1,685	1,448	187
Other Income / (Expense), net	-893	1,158	-576	720	2,314	-938	854	1,685	1,448	187
Income Tax Expense	554	400	1,368	1,084	2,124	1,515	1,021	4,156	1,408	446
Net Income / (Loss) Attributable to Noncontrolling Interest	15	15	18	20	20	21	27	-32	50	66
Basic Earnings per Share	($4.41)	$3.88	$2.97	$3.15	($3.99)	$2.02	$3.01	$0.61	$2.67	$0.94
Weighted Average Basic Shares Outstanding	2.03B	2.02B	2.10B	2.18B	2.24B	2.26B	1.63B	1.65B	1.67B	1.67B
Diluted Earnings per Share	($4.41)	$3.86	$2.95	$3.12	($3.99)	$2.01	$3.01	$0.61	$2.65	$0.93
Weighted Average Diluted Shares Outstanding	2.03B	2.02B	2.10B	2.18B	2.24B	2.26B	1.63B	1.65B	1.67B	1.67B
Weighted Average Basic & Diluted Shares Outstanding	2.03B	2.02B	2.10B	2.18B	2.24B	2.26B	1.63B	1.65B	1.67B	1.67B
Cash Dividends to Common per Share	$2.42	$2.31	$2.19	$2.01	$1.84	$1.68	$1.61	$1.57	$1.53	$1.49

This table shows Bristol-Myers Squibb's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	2,456	72	1,211	1,680	-11,911	1,762	1,928	2,073	2,262	2,022	1,606
Consolidated Net Income / (Loss)	2,462	76	1,215	1,684	-11,908	1,762	1,934	2,077	2,267	2,025	1,608
Net Income / (Loss) Continuing Operations	2,462	76	1,215	1,684	-11,908	1,762	1,934	2,077	2,267	2,025	1,608
Total Pre-Tax Income	2,971	175	1,676	1,286	-11,516	1,674	2,137	1,859	2,770	1,859	2,209
Total Operating Income	3,309	480	1,910	1,559	-11,435	1,303	1,879	1,743	2,357	1,642	2,069
Total Gross Profit	7,980	7,500	8,673	8,802	-4,016	8,132	8,380	8,192	8,696	8,761	8,835
Total Revenue	11,201	12,342	11,892	12,201	11,865	11,477	10,966	11,226	11,337	11,406	11,218
Operating Revenue	11,201	12,342	11,892	12,201	11,865	11,477	10,966	11,226	11,337	11,406	11,218
Total Cost of Revenue	3,221	4,842	3,219	3,399	15,881	3,345	2,586	3,034	2,641	2,645	2,383
Operating Cost of Revenue	3,221	4,842	3,219	3,399	15,881	3,345	2,586	3,034	2,641	2,645	2,383
Total Operating Expenses	4,671	7,020	6,763	7,243	7,419	6,829	6,501	6,449	6,339	7,119	6,766
Selling, General & Admin Expense	1,584	2,136	1,983	1,928	2,367	2,073	2,003	1,934	1,762	2,266	1,930
Research & Development Expense	2,257	3,191	2,374	2,899	2,695	2,478	2,242	2,258	2,321	2,510	2,418
Amortization Expense	830	1,693	2,406	2,416	2,357	2,278	2,256	2,257	2,256	2,343	2,418
Total Other Income / (Expense), net	-339	-305	-234	-273	-81	371	258	116	413	217	140
Other Income / (Expense), net	-339	-305	-234	-273	-81	371	258	116	413	217	140
Income Tax Expense	509	99	461	-398	392	-88	203	-218	503	-166	601
Net Income / (Loss) Attributable to Noncontrolling Interest	6.00	4.00	4.00	4.00	3.00	-	6.00	4.00	5.00	3.00	2.00
Basic Earnings per Share	$1.21	$0.05	$0.60	$0.83	($5.89)	$0.87	$0.94	$0.99	$1.08	$0.95	$0.75
Weighted Average Basic Shares Outstanding	2.04B	2.03B	2.03B	2.03B	2.03B	2.02B	2.03B	2.09B	2.10B	2.10B	2.13B
Diluted Earnings per Share	$1.20	$0.05	$0.60	$0.83	($5.89)	$0.87	$0.93	$0.99	$1.07	$0.95	$0.75
Weighted Average Diluted Shares Outstanding	2.04B	2.03B	2.03B	2.03B	2.03B	2.02B	2.03B	2.09B	2.10B	2.10B	2.13B
Weighted Average Basic & Diluted Shares Outstanding	2.04B	2.03B	2.03B	2.03B	2.03B	2.02B	2.03B	2.09B	2.10B	2.10B	2.13B
Cash Dividends to Common per Share	$0.62	-	$0.60	$0.60	$0.60	-	$0.57	$0.57	$0.57	-	$0.54

This table details how cash moves in and out of Bristol-Myers Squibb's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	-1,172	2,194	-4,991	-657	2,153	5,909	1,531	1,132	1,852	-3,186
Net Cash From Operating Activities	15,190	13,860	13,066	16,207	14,052	8,210	7,066	5,275	3,058	2,105
Net Cash From Continuing Operating Activities	15,190	13,860	13,066	16,207	14,052	8,210	7,066	5,275	3,058	2,105
Net Income / (Loss) Continuing Operations	-8,933	8,040	6,345	7,014	-8,995	3,460	4,947	975	4,507	1,631
Consolidated Net Income / (Loss)	-8,933	8,040	6,345	7,014	-8,995	3,460	4,947	975	4,507	1,631
Depreciation Expense	9,600	9,760	10,276	10,686	10,380	1,746	637	789	382	376
Non-Cash Adjustments To Reconcile Net Income	15,802	1,262	1,412	1,703	12,454	-1,453	1,034	677	-644	935
Changes in Operating Assets and Liabilities, net	-1,279	-5,202	-4,967	-3,196	213	2,769	262	2,598	-1,356	-1,082
Net Cash From Investing Activities	-21,352	-2,295	-1,062	-538	-10,859	-9,913	-2,000	-66	1,480	-1,572
Net Cash From Continuing Investing Activities	-21,352	-2,295	-1,062	-538	-10,859	-9,913	-2,000	-66	1,480	-1,572
Purchase of Property, Plant & Equipment	-1,248	-1,209	-1,118	-973	-753	-836	-951	-1,055	-1,215	-820
Acquisitions	-21,821	-1,169	-4,286	-1,610	-13,084	-24,777	-2,372	-726	-359	-1,111
Purchase of Investments	-769	-1,774	-3,592	-5,478	-4,172	-3,961	-2,305	-5,419	-3,089	-3,143
Divestitures	1,099	909	1,305	748	870	15,852	1,249	736	1,334	708
Sale and/or Maturity of Investments	1,387	948	6,629	6,775	6,280	3,809	2,379	6,398	4,809	2,794
Net Cash From Financing Activities	5,127	-9,416	-16,962	-16,224	-1,151	7,621	-3,535	-4,077	-2,653	-3,624
Net Cash From Continuing Financing Activities	5,127	-9,416	-16,962	-16,224	-1,151	7,621	-3,535	-4,077	-2,653	-3,624
Repayment of Debt	-5,774	-3,999	-11,237	-5,541	-2,475	-9,178	-602	-1,246	0.00	-2,406
Repurchase of Common Equity	0.00	-5,155	-8,001	-6,287	-1,546	-7,300	-320	-2,469	-231	0.00
Payment of Dividends	-4,863	-4,744	-4,634	-4,396	-4,075	-2,679	-2,613	-2,577	-2,547	-2,477
Issuance of Debt	15,870	4,455	5,926	0.00	6,945	26,778	0.00	2,215	125	1,259
Other Financing Activities, net	-106	27	984	-	-	-	-	-	-	-
Effect of Exchange Rate Changes	-137	45	-33	-102	111	-9.00	-	-	-33	-95

This table details how cash moves in and out of Bristol-Myers Squibb's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	528	2,454	1,597	-3,038	-2,185	3,951	-857	-623	-277	1,368	-3,003
Net Cash From Operating Activities	1,954	4,439	5,591	2,326	2,834	4,252	4,751	1,887	2,970	3,306	3,687
Net Cash From Continuing Operating Activities	1,954	4,439	5,591	2,326	2,834	4,252	4,751	1,887	2,970	3,306	3,687
Net Income / (Loss) Continuing Operations	2,462	76	1,215	1,684	-11,908	1,762	1,934	2,077	2,267	2,025	1,608
Consolidated Net Income / (Loss)	2,462	76	1,215	1,684	-11,908	1,762	1,934	2,077	2,267	2,025	1,608
Depreciation Expense	1,012	1,880	2,592	2,596	2,532	2,464	2,435	2,432	2,429	2,521	2,588
Non-Cash Adjustments To Reconcile Net Income	128	1,998	333	748	12,723	498	418	164	182	-158	-28
Changes in Operating Assets and Liabilities, net	-1,648	485	1,451	-2,702	-513	-472	-36	-2,786	-1,908	-1,082	-481
Net Cash From Investing Activities	-499	-196	-219	-1,319	-19,618	-1,346	-410	-329	-210	1,213	-2,081
Net Cash From Continuing Investing Activities	-499	-196	-219	-1,319	-19,618	-1,346	-410	-329	-210	1,213	-2,081
Purchase of Property, Plant & Equipment	-260	-378	-324	-262	-284	-330	-342	-259	-278	-346	-247
Acquisitions	-78	-47	-348	-1,373	-20,053	-581	-326	-184	-78	-116	-3,261
Purchase of Investments	-636	-371	-40	-84	-274	-717	-502	-355	-200	-26	-274
Divestitures	243	333	255	270	241	241	247	194	227	490	221
Sale and/or Maturity of Investments	232	267	238	130	752	41	513	275	119	1,211	1,480
Net Cash From Financing Activities	-993	-1,642	-3,852	-4,023	14,644	967	-5,160	-2,173	-3,050	-3,246	-4,543
Net Cash From Continuing Financing Activities	-993	-1,642	-3,852	-4,023	14,644	967	-5,160	-2,173	-3,050	-3,246	-4,543
Repayment of Debt	368	-405	-2,652	-5,787	3,070	-2,353	-10	-124	-1,512	136	-2,857
Payment of Dividends	-1,258	-1,218	-1,216	-1,217	-1,212	-1,160	-1,191	-1,197	-1,196	-1,145	-1,154
Issuance of Debt	0.00	-	-	2,987	12,883	4,455	-	-	0.00	-	-
Other Financing Activities, net	-103	-19	16	-6.00	-97	25	41	53	-92	179	53
Effect of Exchange Rate Changes	66	-147	77	-22	-45	78	-38	-8.00	13	95	-66

This table presents Bristol-Myers Squibb's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	92,603	95,159	96,820	109,314	118,481	129,944	34,986	33,551	33,707	31,748
Total Current Assets	29,780	31,770	27,273	33,262	30,192	29,354	17,716	14,854	13,704	10,415
Cash & Equivalents	10,346	11,464	9,123	13,979	14,546	12,346	6,911	5,421	4,237	2,385
Short-Term Investments	513	816	130	2,987	1,285	3,047	1,848	1,391	2,113	1,885
Accounts Receivable	10,747	10,921	9,886	9,369	8,501	7,685	5,747	6,300	5,543	4,299
Inventories, net	2,557	2,662	2,339	2,095	2,074	4,293	1,195	1,166	1,241	1,221
Other Current Assets	5,617	5,907	5,795	4,832	3,786	1,983	2,015	576	570	625
Plant, Property, & Equipment, net	7,136	6,646	6,255	6,049	5,886	6,252	5,027	5,001	4,980	4,412
Total Noncurrent Assets	55,687	56,743	63,292	70,003	82,403	94,338	12,243	13,696	15,023	16,921
Long-Term Investments	320	364	0.00	-	433	767	1,775	2,480	2,719	4,660
Goodwill	21,719	21,169	21,149	20,502	20,547	22,488	6,538	6,863	6,875	6,881
Intangible Assets	23,307	27,072	35,859	42,527	53,243	63,969	1,091	1,210	1,385	1,419
Noncurrent Deferred & Refundable Income Taxes	4,236	2,768	1,344	1,439	1,161	510	815	1,610	2,996	2,844
Other Noncurrent Operating Assets	6,105	5,370	4,940	5,535	7,019	6,604	2,024	1,533	1,048	1,117
Total Liabilities & Shareholders' Equity	92,603	95,159	96,820	109,314	118,481	129,944	34,986	33,551	33,707	31,748
Total Liabilities	76,215	65,674	65,702	73,308	80,599	78,246	20,859	21,704	17,360	17,324
Total Current Liabilities	23,774	22,262	21,890	21,868	19,080	18,304	10,654	9,563	8,841	8,017
Short-Term Debt	2,046	3,119	4,264	4,948	2,340	3,346	1,703	987	992	139
Accounts Payable	3,602	3,259	3,040	2,949	2,713	2,445	1,892	2,248	1,664	1,565
Other Current Liabilities	18,126	15,884	14,586	13,971	14,027	12,513	7,059	-	-	-
Total Noncurrent Liabilities	52,441	43,412	43,812	51,440	61,519	59,942	10,205	12,141	8,519	9,307
Long-Term Debt	47,603	36,653	35,056	39,605	48,336	43,387	5,646	6,975	5,716	6,550
Noncurrent Deferred & Payable Income Tax Liabilities	369	338	2,166	4,501	5,407	6,454	19	-	-	-
Other Noncurrent Operating Liabilities	4,469	6,421	6,590	7,334	7,776	10,101	4,540	1,164	1,283	1,429
Commitments & Contingencies	0.00	0.00	0.00	0.00	-	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	16,388	29,485	31,118	36,006	37,882	51,698	14,127	11,847	16,347	14,424
Total Preferred & Common Equity	16,335	29,430	31,061	35,946	37,822	51,598	14,031	11,741	16,177	14,266
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	16,335	29,430	31,061	35,946	37,822	51,598	14,031	11,741	16,177	14,266
Common Stock	46,316	45,976	45,457	44,653	44,617	44,001	2,302	2,119	1,946	1,680
Retained Earnings	14,912	28,766	25,503	23,820	21,281	34,474	34,065	31,160	33,513	31,613
Treasury Stock	-43,655	-43,766	-38,618	-31,259	-26,237	-25,357	-19,574	-19,249	-16,779	-16,559
Accumulated Other Comprehensive Income / (Loss)	-1,238	-1,546	-1,281	-1,268	-1,839	-1,520	-2,762	-2,289	-2,503	-2,468
Other Equity Adjustments	0.00	0.00	-	-	-	0.00	-	-	-	-
Noncontrolling Interest	53	55	57	60	60	100	96	106	170	158

This table presents Bristol-Myers Squibb's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Total Assets	92,427	92,603	93,670	94,646	99,031	95,159	91,263	93,489	94,281	96,820	98,196
Total Current Assets	30,783	29,780	28,075	26,890	28,669	31,770	27,632	28,074	27,086	27,273	26,796
Cash & Equivalents	10,875	10,346	7,890	6,293	9,330	11,464	7,514	8,372	8,995	9,123	7,734
Short-Term Investments	907	513	204	360	340	816	171	358	274	130	1,293
Accounts Receivable	10,801	10,747	11,026	11,423	10,447	10,921	10,304	10,112	10,054	9,886	9,613
Inventories, net	2,666	2,557	3,332	3,077	2,985	2,662	2,436	2,364	2,605	2,339	2,074
Other Current Assets	5,534	5,617	5,623	5,737	5,567	5,907	7,207	6,868	5,158	5,795	6,082
Plant, Property, & Equipment, net	7,213	7,136	6,903	6,845	6,750	6,646	6,481	6,355	6,279	6,255	6,035
Total Noncurrent Assets	54,430	55,687	58,692	60,911	63,612	56,743	56,825	59,060	60,916	63,292	65,365
Long-Term Investments	344	320	324	357	367	364	-	-	-	0.00	-
Goodwill	21,737	21,719	21,751	21,732	21,738	21,169	21,147	21,163	21,162	21,149	21,112
Intangible Assets	22,486	23,307	26,964	29,428	32,760	27,072	28,950	31,303	33,569	35,859	38,179
Noncurrent Deferred & Refundable Income Taxes	3,997	4,236	3,609	3,323	2,723	2,768	1,514	1,572	1,317	1,344	1,329
Other Noncurrent Operating Assets	5,866	6,105	6,044	6,071	6,024	5,370	5,214	5,022	4,868	4,940	4,745
Total Liabilities & Shareholders' Equity	92,427	92,603	93,670	94,646	99,031	95,159	91,263	93,489	94,281	96,820	98,196
Total Liabilities	74,979	76,215	76,470	77,577	82,483	65,674	62,201	61,459	62,395	65,702	65,462
Total Current Liabilities	24,070	23,774	22,638	23,265	25,822	22,262	23,462	20,150	19,085	21,890	18,930
Short-Term Debt	3,554	2,046	1,078	3,531	6,190	3,119	5,467	3,020	2,752	4,264	2,132
Accounts Payable	4,002	3,602	3,469	3,751	3,539	3,259	2,813	3,069	3,194	3,040	2,595
Other Current Liabilities	16,514	18,126	18,091	15,983	16,093	15,884	15,182	14,061	13,139	14,586	14,203
Total Noncurrent Liabilities	50,910	52,441	53,832	54,312	56,661	43,412	38,739	41,309	43,310	43,812	46,532
Long-Term Debt	46,157	47,603	48,674	48,858	49,487	36,653	32,137	34,656	35,078	35,056	36,966
Noncurrent Deferred & Payable Income Tax Liabilities	276	369	430	461	442	338	399	751	1,568	2,166	2,881
Other Noncurrent Operating Liabilities	4,477	4,469	4,728	4,993	6,732	6,421	6,203	5,902	6,664	6,590	6,685
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	17,448	16,388	17,200	17,069	16,548	29,485	29,062	32,030	31,886	31,118	32,734
Total Preferred & Common Equity	17,389	16,335	17,142	17,015	16,490	29,430	28,998	31,973	31,824	31,061	32,671
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	17,388	16,335	17,142	17,015	16,490	29,430	28,998	31,973	31,824	31,061	32,671
Common Stock	46,303	46,316	46,188	46,058	45,947	45,976	45,141	45,591	45,432	45,457	45,248
Retained Earnings	16,106	14,912	16,097	16,103	15,640	28,766	28,218	27,449	26,568	25,503	24,675
Treasury Stock	-43,597	-43,655	-43,675	-43,690	-43,697	-43,766	-43,075	-39,680	-38,808	-38,618	-36,411
Accumulated Other Comprehensive Income / (Loss)	-1,424	-1,238	-1,468	-1,456	-1,400	-1,546	-1,286	-1,387	-1,368	-1,281	-841
Noncontrolling Interest	59	53	58	54	58	55	64	57	62	57	63

This table displays calculated financial ratios and metrics derived from Bristol-Myers Squibb's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	7.32%	-2.50%	-0.49%	9.10%	62.62%	15.89%	8.59%	6.94%	17.31%	4.29%
EBITDA Growth	-93.29%	1.17%	-4.23%	435.31%	-58.27%	23.83%	10.32%	-4.79%	139.66%	-29.35%
EBIT Growth	-199.28%	9.43%	-4.75%	217.86%	-238.11%	-16.64%	16.31%	-13.25%	184.79%	-12.77%
NOPAT Growth	-175.54%	1.73%	6.70%	199.39%	-256.35%	-2.99%	547.38%	-80.76%	129.33%	-32.78%
Net Income Growth	-211.11%	26.71%	-9.54%	177.98%	-359.97%	-30.06%	407.38%	-78.37%	176.33%	-19.62%
EPS Growth	-214.25%	30.85%	-5.45%	178.20%	-298.51%	-33.22%	393.44%	-76.98%	184.95%	-22.50%
Operating Cash Flow Growth	9.60%	6.08%	-19.38%	15.34%	71.16%	16.19%	33.95%	72.50%	45.27%	-33.13%
Free Cash Flow Firm Growth	-130.28%	24.73%	-38.86%	325.41%	105.28%	-1,862.32%	-7.51%	157.63%	74.34%	-77.27%
Invested Capital Growth	-3.10%	-7.47%	-3.79%	-12.04%	-12.13%	651.88%	4.04%	-24.80%	14.80%	4.87%
Revenue Q/Q Growth	1.82%	0.16%	-1.24%	2.02%	7.93%	8.16%	2.38%	1.00%	5.18%	0.18%
EBITDA Q/Q Growth	-63.04%	-1.31%	-0.28%	184.95%	-71.74%	-6.72%	12.14%	-4.23%	30.78%	-28.49%
EBIT Q/Q Growth	-21.79%	-2.14%	0.09%	292.58%	-299.10%	-24.72%	15.64%	-7.03%	33.85%	-14.42%
NOPAT Q/Q Growth	-12.35%	-5.45%	-11.63%	227.79%	-21,598.68%	-30.79%	269.00%	-77.20%	23.88%	-28.02%
Net Income Q/Q Growth	-23.26%	-3.17%	-5.19%	230.25%	-32,025.00%	-39.06%	238.84%	-76.80%	31.75%	-11.65%
EPS Q/Q Growth	-22.84%	-2.03%	-3.91%	231.09%	-1,275.86%	-41.74%	234.44%	-75.98%	32.50%	-12.26%
Operating Cash Flow Q/Q Growth	1.25%	7.33%	-5.44%	4.53%	9.12%	-14.34%	52.68%	-5.82%	22.37%	17.40%
Free Cash Flow Firm Q/Q Growth	23.27%	0.20%	-17.82%	582.50%	105.52%	-854.76%	44.05%	29.89%	-14.79%	6.51%
Invested Capital Q/Q Growth	-6.28%	-3.48%	-2.58%	-4.11%	-1.68%	789.80%	-10.38%	-23.28%	-0.19%	-7.30%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	43.39%	74.21%	76.27%	76.07%	72.31%	69.10%	71.34%	71.05%	74.42%	76.39%
EBITDA Margin	2.53%	40.44%	38.97%	40.50%	8.25%	32.16%	30.10%	29.63%	33.28%	16.29%
Operating Margin	-15.50%	16.18%	17.96%	15.91%	-21.60%	22.62%	22.67%	16.59%	22.99%	11.41%
EBIT Margin	-17.35%	18.75%	16.71%	17.46%	-16.16%	19.03%	26.45%	24.70%	30.45%	12.54%
Profit (Net Income) Margin	-18.49%	17.86%	13.75%	15.12%	-21.16%	13.23%	21.93%	4.69%	23.20%	9.85%
Tax Burden Percent	106.61%	95.26%	82.26%	86.61%	130.91%	69.55%	82.89%	19.00%	76.20%	78.53%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	4.74%	17.74%	13.39%	0.00%	30.45%	17.11%	81.00%	23.80%	21.47%
Return on Invested Capital (ROIC)	-9.40%	11.78%	10.93%	9.41%	-8.32%	8.82%	39.51%	5.34%	26.01%	12.47%
ROIC Less NNEP Spread (ROIC-NNEP)	-20.66%	15.64%	9.29%	11.42%	-16.22%	4.06%	8.15%	-12.00%	-21.94%	7.23%
Return on Net Nonoperating Assets (RNNOA)	-29.54%	14.76%	7.98%	9.58%	-11.76%	1.69%	-1.42%	1.57%	3.28%	-1.38%
Return on Equity (ROE)	-38.95%	26.53%	18.91%	18.99%	-20.08%	10.51%	38.09%	6.92%	29.29%	11.09%
Cash Return on Invested Capital (CROIC)	-6.25%	19.54%	14.79%	22.21%	4.59%	-144.22%	35.55%	33.66%	12.23%	7.72%
Operating Return on Assets (OROA)	-8.93%	8.79%	7.48%	7.11%	-5.53%	6.03%	17.42%	15.26%	18.07%	6.34%
Return on Assets (ROA)	-9.52%	8.38%	6.16%	6.16%	-7.24%	4.20%	14.44%	2.90%	13.77%	4.98%
Return on Common Equity (ROCE)	-38.86%	26.48%	18.87%	18.95%	-20.05%	10.48%	37.80%	6.85%	28.98%	10.98%
Return on Equity Simple (ROE_SIMPLE)	-54.69%	27.32%	20.43%	19.51%	-23.78%	6.71%	35.26%	8.30%	27.86%	11.43%
Net Operating Profit after Tax (NOPAT)	-5,240	6,937	6,819	6,390	-6,430	4,112	4,239	655	3,404	1,484
NOPAT Margin	-10.85%	15.41%	14.77%	13.78%	-15.12%	15.73%	18.79%	3.15%	17.52%	8.96%
Net Nonoperating Expense Percent (NNEP)	11.26%	-3.86%	1.64%	-2.01%	7.90%	4.76%	31.36%	17.35%	47.95%	5.24%
Return On Investment Capital (ROIC_SIMPLE)	-7.94%	10.02%	9.68%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	56.61%	25.79%	23.73%	23.93%	27.69%	30.90%	28.66%	28.95%	25.58%	23.61%
SG&A Expenses to Revenue	17.42%	17.27%	16.93%	16.58%	18.02%	18.63%	20.17%	22.87%	25.63%	29.23%
R&D to Revenue	23.10%	20.66%	20.60%	21.98%	23.63%	23.52%	28.07%	31.13%	25.80%	35.75%
Operating Expenses to Revenue	58.89%	58.03%	58.32%	60.17%	93.91%	46.49%	48.67%	54.47%	51.43%	64.98%
Earnings before Interest and Taxes (EBIT)	-8,379	8,440	7,713	8,098	-6,871	4,975	5,968	5,131	5,915	2,077
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	1,221	18,200	17,989	18,784	3,509	8,409	6,791	6,156	6,466	2,698
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	6.95	3.34	4.48	3.56	3.35	1.76	5.09	7.00	4.82	6.30
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	11.15	22.41	9.84	15.07
Price to Revenue (P/Rev)	2.35	2.18	3.01	2.76	2.98	3.48	3.16	3.96	4.01	5.43
Price to Earnings (P/E)	0.00	12.25	21.98	18.32	0.00	26.47	14.51	81.62	17.48	57.45
Dividend Yield	4.29%	4.72%	3.30%	3.40%	3.28%	2.94%	3.66%	3.11%	3.26%	2.76%
Earnings Yield	0.00%	8.16%	4.55%	5.46%	0.00%	3.78%	6.89%	1.23%	5.72%	1.74%
Enterprise Value to Invested Capital (EV/IC)	2.77	2.22	2.77	2.45	2.23	1.48	6.24	7.70	5.41	7.21
Enterprise Value to Revenue (EV/Rev)	3.15	2.79	3.67	3.36	3.79	4.66	3.03	3.90	3.90	5.30
Enterprise Value to EBITDA (EV/EBITDA)	124.48	6.89	9.41	8.29	45.95	14.47	10.06	13.15	11.71	32.55
Enterprise Value to EBIT (EV/EBIT)	0.00	14.87	21.94	19.24	0.00	24.46	11.45	15.78	12.80	42.29
Enterprise Value to NOPAT (EV/NOPAT)	0.00	18.09	24.81	24.38	0.00	29.60	16.11	123.65	22.25	59.18
Enterprise Value to Operating Cash Flow (EV/OCF)	10.01	9.05	12.95	9.61	11.48	14.82	9.67	15.35	24.76	41.72
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	10.90	18.34	10.32	45.46	0.00	17.91	19.63	47.31	95.66
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	3.03	1.35	1.26	1.24	1.34	0.90	0.52	0.67	0.41	0.46
Long-Term Debt to Equity	2.90	1.24	1.13	1.10	1.28	0.84	0.40	0.59	0.35	0.45
Financial Leverage	1.43	0.94	0.86	0.84	0.73	0.42	-0.17	-0.13	-0.15	-0.19
Leverage Ratio	4.09	3.17	3.07	3.08	2.77	2.51	2.64	2.39	2.13	2.23
Compound Leverage Factor	4.09	3.17	3.07	3.08	2.77	2.51	2.64	2.39	2.13	2.23
Debt to Total Capital	75.18%	57.43%	55.82%	55.30%	57.22%	47.48%	34.22%	40.19%	29.10%	31.68%
Short-Term Debt to Total Capital	3.10%	4.50%	6.05%	6.14%	2.64%	3.40%	7.93%	4.98%	4.30%	0.66%
Long-Term Debt to Total Capital	72.09%	52.92%	49.77%	49.16%	54.58%	44.08%	26.29%	35.21%	24.79%	31.02%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.08%	0.08%	0.08%	0.07%	0.07%	0.10%	0.45%	0.54%	0.74%	0.75%
Common Equity to Total Capital	24.74%	42.49%	44.10%	44.62%	42.71%	52.42%	65.33%	59.27%	70.17%	67.57%
Debt to EBITDA	40.66	2.19	2.19	2.37	14.44	5.56	1.08	1.29	1.04	2.48
Net Debt to EBITDA	31.51	1.49	1.67	1.47	9.81	3.64	-0.47	-0.22	-0.37	-0.83
Long-Term Debt to EBITDA	38.99	2.01	1.95	2.11	13.77	5.16	0.83	1.13	0.88	2.43
Debt to NOPAT	-9.47	5.73	5.77	6.97	-7.88	11.36	1.73	12.16	1.97	4.51
Net Debt to NOPAT	-7.34	3.91	4.41	4.32	-5.35	7.43	-0.75	-2.03	-0.69	-1.51
Long-Term Debt to NOPAT	-9.08	5.28	5.14	6.20	-7.52	10.55	1.33	10.65	1.68	4.41
Altman Z-Score	1.42	2.21	2.45	2.15	1.48	1.50	4.87	4.89	5.41	5.34
Noncontrolling Interest Sharing Ratio	0.24%	0.18%	0.17%	0.16%	0.18%	0.30%	0.78%	0.98%	1.07%	0.98%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.25	1.43	1.25	1.52	1.58	1.60	1.66	1.55	1.55	1.30
Quick Ratio	0.91	1.04	0.87	1.20	1.28	1.26	1.36	1.37	1.35	1.07
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-3,485	11,509	9,227	15,091	3,548	-67,217	3,814	4,124	1,601	918
Operating Cash Flow to CapEx	1,217.15%	1,146.40%	1,168.69%	1,665.67%	1,866.14%	982.06%	743.01%	500.00%	251.69%	256.71%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.51	0.47	0.45	0.41	0.34	0.32	0.66	0.62	0.59	0.51
Accounts Receivable Turnover	4.46	4.33	4.79	5.19	5.25	3.89	3.75	3.51	3.95	4.31
Inventory Turnover	10.48	4.64	4.94	5.32	3.70	2.94	5.48	5.00	4.04	2.81
Fixed Asset Turnover	7.01	6.98	7.50	7.77	7.01	4.64	4.50	4.16	4.14	3.75
Accounts Payable Turnover	7.97	3.69	3.66	3.92	4.56	3.73	3.12	3.07	3.08	1.93
Days Sales Outstanding (DSO)	81.87	84.37	76.13	70.31	69.48	93.76	97.45	104.03	92.46	84.74
Days Inventory Outstanding (DIO)	34.84	78.64	73.89	68.55	98.70	123.99	66.63	73.04	90.42	129.84
Days Payable Outstanding (DPO)	45.80	99.05	99.80	93.10	79.96	97.98	116.83	118.71	118.59	189.18
Cash Conversion Cycle (CCC)	70.91	63.96	50.22	45.76	88.22	119.76	47.25	58.36	64.29	25.40
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	54,858	56,613	61,185	63,593	72,294	82,271	10,942	10,517	13,986	12,183
Invested Capital Turnover	0.87	0.76	0.74	0.68	0.55	0.56	2.10	1.70	1.48	1.39
Increase / (Decrease) in Invested Capital	-1,755	-4,572	-2,408	-8,701	-9,977	71,329	425	-3,469	1,803	566
Enterprise Value (EV)	151,984	125,477	169,192	155,767	161,256	121,711	68,308	80,969	75,730	87,831
Market Capitalization	113,461	98,294	139,068	128,120	126,784	91,038	71,397	82,193	77,921	89,914
Book Value per Share	$8.05	$14.46	$14.61	$16.19	$16.74	$31.67	$8.60	$7.17	$9.68	$8.55
Tangible Book Value per Share	($14.15)	($9.24)	($12.20)	($12.20)	($15.92)	($21.40)	$3.92	$2.24	$4.74	$3.58
Total Capital	66,037	69,257	70,438	80,559	88,558	98,431	21,476	19,809	23,055	21,113
Total Debt	49,649	39,772	39,320	44,553	50,676	46,733	7,349	7,962	6,708	6,689
Total Long-Term Debt	47,603	36,653	35,056	39,605	48,336	43,387	5,646	6,975	5,716	6,550
Net Debt	38,470	27,128	30,067	27,587	34,412	30,573	-3,185	-1,330	-2,361	-2,241
Capital Expenditures (CapEx)	1,248	1,209	1,118	973	753	836	951	1,055	1,215	820
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-2,807	347	394	-624	-2,379	-997	6.00	-534	-495	-1,733
Debt-free Net Working Capital (DFNWC)	8,052	12,627	9,647	16,342	13,452	14,396	8,765	6,278	5,855	2,537
Net Working Capital (NWC)	6,006	9,508	5,383	11,394	11,112	11,050	7,062	5,291	4,863	2,398
Net Nonoperating Expense (NNE)	3,693	-1,103	474	-624	2,566	652	-708	-320	-1,103	-147
Net Nonoperating Obligations (NNO)	38,470	27,128	30,067	27,587	34,412	30,573	-3,185	-1,330	-2,361	-2,241
Total Depreciation and Amortization (D&A)	9,600	9,760	10,276	10,686	10,380	3,434	823	1,025	551	621
Debt-free, Cash-free Net Working Capital to Revenue	-5.81%	0.77%	0.85%	-1.35%	-5.60%	-3.81%	0.03%	-2.57%	-2.55%	-10.47%
Debt-free Net Working Capital to Revenue	16.67%	28.06%	20.90%	35.23%	31.64%	55.06%	38.85%	30.22%	30.14%	15.32%
Net Working Capital to Revenue	12.43%	21.13%	11.66%	24.56%	26.13%	42.26%	31.30%	25.47%	25.03%	14.48%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($4.41)	$3.88	$2.97	$3.15	($3.99)	$2.02	$3.01	$0.61	$2.67	$0.94
Adjusted Weighted Average Basic Shares Outstanding	2.03B	2.02B	2.10B	2.18B	2.24B	2.26B	1.63B	1.63B	1.67B	1.67B
Adjusted Diluted Earnings per Share	($4.41)	$3.86	$2.95	$3.12	($3.99)	$2.01	$3.01	$0.61	$2.65	$0.93
Adjusted Weighted Average Diluted Shares Outstanding	2.03B	2.02B	2.10B	2.18B	2.24B	2.26B	1.63B	1.63B	1.67B	1.67B
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$2.02	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	2.03B	2.02B	2.10B	2.18B	2.24B	2.26B	1.63B	1.63B	1.67B	1.67B
Normalized Net Operating Profit after Tax (NOPAT)	-5,240	6,937	6,819	6,390	-6,430	4,112	4,239	2,412	3,404	1,484
Normalized NOPAT Margin	-10.85%	15.41%	14.77%	13.78%	-15.12%	15.73%	18.79%	11.61%	17.52%	8.96%
Pre Tax Income Margin	-17.35%	18.75%	16.71%	17.46%	-16.16%	19.03%	26.45%	24.70%	30.45%	12.54%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	-54.44%	59.01%	73.03%	62.67%	-45.30%	77.43%	52.82%	264.31%	56.51%	151.87%
Augmented Payout Ratio	-54.44%	123.12%	199.13%	152.31%	-62.49%	288.41%	59.29%	517.54%	61.64%	151.87%

This table displays calculated financial ratios and metrics derived from Bristol-Myers Squibb's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-5.60%	7.54%	8.44%	8.69%	4.66%	0.62%	-2.25%	-5.56%	-2.67%	-4.83%	-3.49%
EBITDA Growth	144.32%	-50.34%	-6.65%	-9.53%	-272.80%	-5.53%	-4.69%	-5.51%	21.73%	-1.15%	-1.78%
EBIT Growth	125.79%	-89.55%	-21.57%	-30.82%	-515.74%	-9.95%	-3.26%	-5.06%	64.20%	0.38%	2.41%
NOPAT Growth	134.26%	-84.80%	-18.58%	4.83%	-514.96%	-23.32%	12.91%	19.01%	8.58%	-37.59%	19.75%
Net Income Growth	120.68%	-95.69%	-37.18%	-18.92%	-625.28%	-12.99%	20.27%	45.35%	76.70%	-14.63%	3.61%
EPS Growth	120.37%	-94.25%	-35.48%	-16.16%	-650.47%	-8.42%	24.00%	50.00%	81.36%	-11.22%	8.70%
Operating Cash Flow Growth	-31.05%	4.40%	17.68%	23.26%	-4.58%	28.61%	28.86%	-16.54%	-22.09%	-18.51%	-29.98%
Free Cash Flow Firm Growth	201.58%	-66.96%	-74.24%	-76.89%	-411.26%	41.63%	16.57%	-72.81%	-71.18%	-63.72%	-40.75%
Invested Capital Growth	-11.51%	-3.10%	-0.21%	2.41%	2.88%	-7.47%	-6.61%	-0.84%	-1.95%	-3.79%	-5.30%
Revenue Q/Q Growth	-9.24%	3.78%	-2.53%	2.83%	3.38%	4.66%	-2.32%	-0.98%	-0.60%	1.68%	-5.63%
EBITDA Q/Q Growth	93.77%	-51.85%	9.94%	143.21%	-317.11%	-9.49%	6.55%	-17.46%	18.70%	-8.69%	5.64%
EBIT Q/Q Growth	1,597.14%	-89.56%	30.33%	111.17%	-787.93%	-21.67%	14.95%	-32.89%	49.00%	-15.84%	12.82%
NOPAT Q/Q Growth	1,215.42%	-84.95%	-32.18%	125.50%	-683.63%	-19.35%	-12.68%	0.95%	7.85%	18.76%	-7.96%
Net Income Q/Q Growth	3,139.47%	-93.74%	-27.85%	114.14%	-775.82%	-8.89%	-6.88%	-8.38%	11.95%	25.93%	12.53%
EPS Q/Q Growth	2,300.00%	-91.67%	-27.71%	114.09%	-777.01%	-6.45%	-6.06%	-7.48%	12.63%	26.67%	13.64%
Operating Cash Flow Q/Q Growth	-55.98%	-20.60%	140.37%	-17.93%	-33.35%	-10.50%	151.78%	-36.46%	-10.16%	-10.33%	63.07%
Free Cash Flow Firm Q/Q Growth	404.17%	30.32%	164.56%	105.84%	-263.97%	1.61%	137.36%	-21.29%	-25.39%	-16.37%	-44.63%
Invested Capital Q/Q Growth	0.32%	-6.28%	-6.27%	0.42%	9.85%	-3.48%	-3.80%	0.88%	-1.21%	-2.58%	2.13%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	71.24%	60.77%	72.93%	72.14%	-33.85%	70.85%	76.42%	72.97%	76.70%	76.81%	78.76%
EBITDA Margin	35.55%	16.65%	35.89%	31.82%	-75.72%	36.05%	41.69%	38.22%	45.86%	38.40%	42.76%
Operating Margin	29.54%	3.89%	16.06%	12.78%	-96.38%	11.35%	17.13%	15.53%	20.79%	14.40%	18.44%
EBIT Margin	26.52%	1.42%	14.09%	10.54%	-97.06%	14.59%	19.49%	16.56%	24.43%	16.30%	19.69%
Profit (Net Income) Margin	21.98%	0.62%	10.22%	13.80%	-100.36%	15.35%	17.64%	18.50%	20.00%	17.75%	14.33%
Tax Burden Percent	82.87%	43.43%	72.49%	130.95%	103.40%	105.26%	90.50%	111.73%	81.84%	108.93%	72.79%
Interest Burden Percent	100.03%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	17.13%	56.57%	27.51%	-30.95%	0.00%	-5.26%	9.50%	-11.73%	18.16%	-8.93%	27.21%
Return on Invested Capital (ROIC)	19.90%	1.46%	9.43%	12.61%	-50.10%	9.13%	11.47%	12.80%	12.78%	11.60%	9.72%
ROIC Less NNEP Spread (ROIC-NNEP)	19.22%	1.06%	8.95%	11.65%	-60.62%	10.50%	12.26%	13.25%	13.93%	12.42%	10.06%
Return on Net Nonoperating Assets (RNNOA)	47.06%	1.52%	13.72%	17.63%	-92.87%	9.91%	11.83%	11.83%	12.84%	10.67%	8.50%
Return on Equity (ROE)	66.96%	2.98%	23.14%	30.24%	-142.97%	19.04%	23.31%	24.63%	25.62%	22.27%	18.21%
Cash Return on Invested Capital (CROIC)	23.23%	-6.25%	-7.75%	-9.98%	-10.27%	19.54%	18.91%	12.54%	13.31%	14.79%	17.39%
Operating Return on Assets (OROA)	13.19%	0.73%	7.23%	5.21%	-45.72%	6.84%	9.24%	7.72%	11.35%	7.30%	8.80%
Return on Assets (ROA)	10.94%	0.32%	5.24%	6.82%	-47.28%	7.20%	8.37%	8.63%	9.29%	7.95%	6.41%
Return on Common Equity (ROCE)	66.73%	2.97%	23.08%	30.17%	-142.61%	19.00%	23.26%	24.59%	25.57%	22.23%	18.18%
Return on Equity Simple (ROE_SIMPLE)	31.27%	0.00%	-42.28%	-38.37%	-37.20%	0.00%	28.63%	24.95%	23.03%	0.00%	20.48%
Net Operating Profit after Tax (NOPAT)	2,742	208	1,385	2,041	-8,005	1,371	1,701	1,947	1,929	1,789	1,506
NOPAT Margin	24.48%	1.69%	11.64%	16.73%	-67.46%	11.95%	15.51%	17.35%	17.02%	15.68%	13.43%
Net Nonoperating Expense Percent (NNEP)	0.67%	0.40%	0.48%	0.96%	10.52%	-1.37%	-0.78%	-0.45%	-1.15%	-0.82%	-0.34%
Return On Investment Capital (ROIC_SIMPLE)	4.08%	0.32%	-	-	-	1.98%	-	-	-	2.54%	-
Cost of Revenue to Revenue	28.76%	39.23%	27.07%	27.86%	133.85%	29.15%	23.58%	27.03%	23.30%	23.19%	21.24%
SG&A Expenses to Revenue	14.14%	17.31%	16.68%	15.80%	19.95%	18.06%	18.27%	17.23%	15.54%	19.87%	17.20%
R&D to Revenue	20.15%	25.85%	19.96%	23.76%	22.71%	21.59%	20.45%	20.11%	20.47%	22.01%	21.55%
Operating Expenses to Revenue	41.70%	56.88%	56.87%	59.36%	62.53%	59.50%	59.28%	57.45%	55.91%	62.41%	60.31%
Earnings before Interest and Taxes (EBIT)	2,970	175	1,676	1,286	-11,516	1,674	2,137	1,859	2,770	1,859	2,209
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	3,982	2,055	4,268	3,882	-8,984	4,138	4,572	4,291	5,199	4,380	4,797
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	7.04	6.95	6.05	4.87	6.61	3.34	3.94	3.97	4.35	4.48	4.40
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	2.57	2.35	2.19	1.78	2.40	2.18	2.54	2.81	3.02	3.01	3.08
Price to Earnings (P/E)	22.59	0.00	0.00	0.00	0.00	12.25	13.79	15.93	18.92	21.98	21.54
Dividend Yield	4.01%	4.29%	4.63%	5.72%	4.31%	4.72%	4.11%	3.68%	3.32%	3.30%	3.13%
Earnings Yield	4.43%	0.00%	0.00%	0.00%	0.00%	8.16%	7.25%	6.28%	5.28%	4.55%	4.64%
Enterprise Value to Invested Capital (EV/IC)	2.91	2.77	2.48	2.06	2.49	2.22	2.46	2.56	2.76	2.77	2.77
Enterprise Value to Revenue (EV/Rev)	3.36	3.15	3.06	2.76	3.40	2.79	3.21	3.45	3.64	3.67	3.72
Enterprise Value to EBITDA (EV/EBITDA)	11.28	124.48	43.93	35.58	38.53	6.89	7.82	8.35	8.83	9.41	9.64
Enterprise Value to EBIT (EV/EBIT)	26.21	0.00	0.00	0.00	0.00	14.87	16.72	17.92	18.98	21.94	22.57
Enterprise Value to NOPAT (EV/NOPAT)	24.78	0.00	0.00	0.00	0.00	18.09	19.66	21.76	24.11	24.81	22.54
Enterprise Value to Operating Cash Flow (EV/OCF)	11.19	10.01	9.67	9.06	11.28	9.05	11.17	13.16	13.66	12.95	12.59
Enterprise Value to Free Cash Flow (EV/FCFF)	11.76	0.00	0.00	0.00	0.00	10.90	12.56	20.29	20.55	18.34	15.49
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	2.85	3.03	2.89	3.07	3.36	1.35	1.29	1.18	1.19	1.26	1.19
Long-Term Debt to Equity	2.65	2.90	2.83	2.86	2.99	1.24	1.11	1.08	1.10	1.13	1.13
Financial Leverage	2.45	1.43	1.53	1.51	1.53	0.94	0.97	0.89	0.92	0.86	0.84
Leverage Ratio	5.63	4.09	4.00	3.83	3.99	3.17	3.07	3.00	3.11	3.07	2.99
Compound Leverage Factor	5.63	4.09	4.00	3.83	3.99	3.17	3.07	3.00	3.11	3.07	2.99
Debt to Total Capital	74.02%	75.18%	74.31%	75.43%	77.09%	57.43%	56.41%	54.05%	54.26%	55.82%	54.43%
Short-Term Debt to Total Capital	5.29%	3.10%	1.61%	5.08%	8.57%	4.50%	8.20%	4.33%	3.95%	6.05%	2.97%
Long-Term Debt to Total Capital	68.73%	72.09%	72.70%	70.34%	68.52%	52.92%	48.21%	49.72%	50.32%	49.77%	51.46%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.09%	0.08%	0.09%	0.08%	0.08%	0.08%	0.10%	0.08%	0.09%	0.08%	0.09%
Common Equity to Total Capital	25.89%	24.74%	25.60%	24.50%	22.83%	42.49%	43.50%	45.87%	45.65%	44.10%	45.48%
Debt to EBITDA	3.50	40.66	15.06	14.52	13.86	2.19	2.04	2.02	2.00	2.19	2.17
Net Debt to EBITDA	2.65	31.51	12.51	12.58	11.36	1.49	1.62	1.55	1.51	1.67	1.67
Long-Term Debt to EBITDA	3.25	38.99	14.73	13.54	12.32	2.01	1.74	1.86	1.85	1.95	2.05
Debt to NOPAT	7.69	-9.47	-10.67	-11.18	-12.22	5.73	5.13	5.26	5.46	5.77	5.07
Net Debt to NOPAT	5.82	-7.34	-8.86	-9.68	-10.02	3.91	4.08	4.04	4.12	4.41	3.90
Long-Term Debt to NOPAT	7.14	-9.08	-10.44	-10.43	-10.86	5.28	4.38	4.84	5.07	5.14	4.79
Altman Z-Score	1.93	1.72	1.69	1.46	1.13	1.97	2.16	2.30	2.41	2.25	2.32
Noncontrolling Interest Sharing Ratio	0.35%	0.24%	0.26%	0.23%	0.25%	0.18%	0.21%	0.18%	0.20%	0.17%	0.19%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.28	1.25	1.24	1.16	1.11	1.43	1.18	1.39	1.42	1.25	1.42
Quick Ratio	0.94	0.91	0.84	0.78	0.78	1.04	0.77	0.94	1.01	0.87	0.98
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	9,899	1,963	1,507	569	-9,746	5,943	5,850	2,464	3,131	4,197	5,018
Operating Cash Flow to CapEx	751.54%	1,174.34%	1,725.62%	887.79%	997.89%	1,288.48%	1,389.18%	728.57%	1,068.35%	955.49%	1,492.71%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.50	0.51	0.51	0.49	0.47	0.47	0.47	0.47	0.46	0.45	0.45
Accounts Receivable Turnover	4.48	4.46	4.45	4.32	4.44	4.33	4.51	4.72	4.94	4.79	4.96
Inventory Turnover	5.20	10.48	8.96	9.27	8.89	4.64	4.84	4.75	4.58	4.94	4.53
Fixed Asset Turnover	6.82	7.01	7.09	7.05	6.99	6.98	7.18	7.33	7.44	7.50	7.85
Accounts Payable Turnover	3.89	7.97	8.23	7.39	7.38	3.69	4.03	3.60	3.52	3.66	3.63
Days Sales Outstanding (DSO)	81.40	81.87	82.06	84.50	82.17	84.37	80.89	77.41	73.90	76.13	73.64
Days Inventory Outstanding (DIO)	70.25	34.84	40.73	39.39	41.06	78.64	75.47	76.83	79.65	73.89	80.56
Days Payable Outstanding (DPO)	93.74	45.80	44.36	49.37	49.46	99.05	90.50	101.47	103.83	99.80	100.58
Cash Conversion Cycle (CCC)	57.91	70.91	78.43	74.52	73.77	63.96	65.86	52.77	49.73	50.22	53.62
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	55,031	54,858	58,534	62,448	62,188	56,613	58,656	60,976	60,447	61,185	62,805
Invested Capital Turnover	0.81	0.87	0.81	0.75	0.74	0.76	0.74	0.74	0.75	0.74	0.72
Increase / (Decrease) in Invested Capital	-7,157	-1,755	-122	1,472	1,741	-4,572	-4,149	-517	-1,202	-2,408	-3,512
Enterprise Value (EV)	160,085	151,984	145,128	128,358	154,774	125,477	144,239	155,891	166,961	169,192	173,929
Market Capitalization	122,441	113,461	103,736	82,925	109,076	98,294	114,256	126,888	138,338	139,068	143,795
Book Value per Share	$8.57	$8.05	$8.46	$8.39	$8.13	$14.46	$13.88	$15.22	$15.16	$14.61	$15.30
Tangible Book Value per Share	($13.22)	($14.15)	($15.57)	($16.84)	($18.75)	($9.24)	($10.10)	($9.75)	($10.91)	($12.20)	($12.47)
Total Capital	67,159	66,037	66,952	69,458	72,225	69,257	66,666	69,706	69,716	70,438	71,832
Total Debt	49,711	49,649	49,752	52,389	55,677	39,772	37,604	37,676	37,830	39,320	39,098
Total Long-Term Debt	46,157	47,603	48,674	48,858	49,487	36,653	32,137	34,656	35,078	35,056	36,966
Net Debt	37,585	38,470	41,334	45,379	45,640	27,128	29,919	28,946	28,561	30,067	30,071
Capital Expenditures (CapEx)	260	378	324	262	284	330	342	259	278	346	247
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1,515	-2,807	-1,579	503	-633	347	1,952	2,214	1,484	394	971
Debt-free Net Working Capital (DFNWC)	10,267	8,052	6,515	7,156	9,037	12,627	9,637	10,944	10,753	9,647	9,998
Net Working Capital (NWC)	6,713	6,006	5,437	3,625	2,847	9,508	4,170	7,924	8,001	5,383	7,866
Net Nonoperating Expense (NNE)	280	132	170	357	3,904	-391	-233	-130	-338	-236	-102
Net Nonoperating Obligations (NNO)	37,583	38,470	41,334	45,379	45,640	27,128	29,594	28,946	28,561	30,067	30,071
Total Depreciation and Amortization (D&A)	1,012	1,880	2,592	2,596	2,532	2,464	2,435	2,432	2,429	2,521	2,588
Debt-free, Cash-free Net Working Capital to Revenue	-3.18%	-5.81%	-3.33%	1.08%	-1.39%	0.77%	4.34%	4.90%	3.24%	0.85%	2.08%
Debt-free Net Working Capital to Revenue	21.55%	16.67%	13.73%	15.39%	19.85%	28.06%	21.45%	24.22%	23.45%	20.90%	21.39%
Net Working Capital to Revenue	14.09%	12.43%	11.46%	7.79%	6.25%	21.13%	9.28%	17.54%	17.45%	11.66%	16.83%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.21	$0.05	$0.60	$0.83	($5.89)	$0.87	$0.94	$0.99	$1.08	$0.95	$0.75
Adjusted Weighted Average Basic Shares Outstanding	2.04B	2.03B	2.03B	2.03B	2.03B	2.02B	2.03B	2.09B	2.10B	2.10B	2.13B
Adjusted Diluted Earnings per Share	$1.20	$0.05	$0.60	$0.83	($5.89)	$0.87	$0.93	$0.99	$1.07	$0.95	$0.75
Adjusted Weighted Average Diluted Shares Outstanding	2.04B	2.03B	2.03B	2.03B	2.03B	2.02B	2.03B	2.09B	2.10B	2.10B	2.13B
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	2.04B	2.03B	2.03B	2.03B	2.03B	2.02B	2.03B	2.09B	2.10B	2.10B	2.13B
Normalized Net Operating Profit after Tax (NOPAT)	2,742	336	1,385	1,091	-8,005	912	1,701	1,220	1,929	1,149	1,506
Normalized NOPAT Margin	24.48%	2.72%	11.64%	8.94%	-67.46%	7.95%	15.51%	10.87%	17.02%	10.08%	13.43%
Pre Tax Income Margin	26.52%	1.42%	14.09%	10.54%	-97.06%	14.59%	19.49%	16.56%	24.43%	16.30%	19.69%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	90.29%	-54.44%	-66.30%	-73.22%	-77.59%	59.01%	56.96%	58.82%	63.38%	73.03%	68.56%
Augmented Payout Ratio	90.29%	-54.44%	-66.30%	-134.50%	-157.54%	123.12%	148.14%	110.92%	107.74%	199.13%	193.13%

Frequently Asked Questions About Bristol-Myers Squibb's Financials

When does Bristol-Myers Squibb's fiscal year end?

According to the most recent income statement we have on file, Bristol-Myers Squibb's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Bristol-Myers Squibb's net income changed over the last 9 years?

Bristol-Myers Squibb's net income appears to be on a downward trend, with a most recent value of -$8.93 billion in 2024, falling from $1.63 billion in 2015. The previous period was $8.04 billion in 2023. See Bristol-Myers Squibb's forecast for analyst expectations on what’s next for the company.

What is Bristol-Myers Squibb's operating income?

Bristol-Myers Squibb's total operating income in 2024 was -$7.49 billion, based on the following breakdown:

Total Gross Profit: $20.96 billion
Total Operating Expenses: $28.45 billion

How has Bristol-Myers Squibb revenue changed over the last 9 years?

Over the last 9 years, Bristol-Myers Squibb's total revenue changed from $16.56 billion in 2015 to $48.30 billion in 2024, a change of 191.7%.

How much debt does Bristol-Myers Squibb have?

Bristol-Myers Squibb's total liabilities were at $76.22 billion at the end of 2024, a 16.1% increase from 2023, and a 339.9% increase since 2015.

How much cash does Bristol-Myers Squibb have?

In the past 9 years, Bristol-Myers Squibb's cash and equivalents has ranged from $2.39 billion in 2015 to $14.55 billion in 2020, and is currently $10.35 billion as of their latest financial filing in 2024.

How has Bristol-Myers Squibb's book value per share changed over the last 9 years?

Over the last 9 years, Bristol-Myers Squibb's book value per share changed from 8.55 in 2015 to 8.05 in 2024, a change of -5.8%.

Related Companies

This page (NYSE:BMY) was last updated on 5/30/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bristol-Myers Squibb (BMY) Financials

Frequently Asked Questions About Bristol-Myers Squibb's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bristol-Myers Squibb (BMY) Financials

Annual Income Statements for Bristol-Myers Squibb

Quarterly Income Statements for Bristol-Myers Squibb

Annual Cash Flow Statements for Bristol-Myers Squibb

Quarterly Cash Flow Statements for Bristol-Myers Squibb

Annual Balance Sheets for Bristol-Myers Squibb

Quarterly Balance Sheets for Bristol-Myers Squibb

Annual Metrics And Ratios for Bristol-Myers Squibb

Quarterly Metrics And Ratios for Bristol-Myers Squibb

Frequently Asked Questions About Bristol-Myers Squibb's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools